46,863 Shares in Haemonetics Corporation $HAE Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd purchased a new position in shares of Haemonetics Corporation (NYSE:HAE) in the 3rd quarter, Holdings Channel reports. The firm purchased 46,863 shares of the medical instruments supplier’s stock, valued at approximately $2,284,000.

A number of other hedge funds also recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Haemonetics by 3.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock valued at $1,877,000 after buying an additional 971 shares during the period. Caxton Associates LLP acquired a new position in Haemonetics in the first quarter valued at $216,000. United Services Automobile Association purchased a new stake in Haemonetics during the first quarter valued at about $212,000. Empowered Funds LLC increased its stake in Haemonetics by 9.1% during the first quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock worth $283,000 after acquiring an additional 372 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Haemonetics by 6.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock worth $9,923,000 after purchasing an additional 9,051 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Price Performance

HAE opened at $66.10 on Thursday. Haemonetics Corporation has a twelve month low of $47.31 and a twelve month high of $87.32. The firm has a market cap of $3.09 billion, a price-to-earnings ratio of 19.33, a PEG ratio of 1.41 and a beta of 0.29. The company has a current ratio of 1.64, a quick ratio of 1.03 and a debt-to-equity ratio of 1.08. The company has a fifty day simple moving average of $78.90 and a 200 day simple moving average of $65.57.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share for the quarter, beating analysts’ consensus estimates of $1.12 by $0.15. The company had revenue of $327.32 million during the quarter, compared to analysts’ expectations of $311.61 million. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The firm’s revenue for the quarter was down 5.3% on a year-over-year basis. During the same period in the prior year, the company posted $1.12 EPS. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Equities research analysts expect that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on HAE. Barrington Research boosted their target price on Haemonetics from $90.00 to $93.00 and gave the stock an “outperform” rating in a report on Monday, January 12th. Needham & Company LLC downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Monday, December 15th. CJS Securities raised shares of Haemonetics to a “strong-buy” rating in a research report on Thursday, December 11th. Robert W. Baird raised their target price on shares of Haemonetics from $87.00 to $99.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haemonetics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Haemonetics currently has a consensus rating of “Moderate Buy” and an average target price of $84.40.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.